Diagnostica Stago
13
2
2
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
15.4%
2 terminated/withdrawn out of 13 trials
77.8%
-8.7% vs industry average
8%
1 trials in Phase 3/4
29%
2 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Exclusion of Intra-atrial Thrombus Before Catheter Ablation
Role: collaborator
Thrombin Generation and Prediction of Thromboembolic Events in Oncology Patients at Risk
Role: collaborator
Thrombin Generation Parameters and Bleeding in Patients Treated With Anticoagulants for Cancer Associated Thrombosis
Role: collaborator
ThRombosis ExclUsion STudy
Role: lead
Evaluation of the Inter-center Variability of the Measurement of Thrombin Generation by the ST Genesia System
Role: collaborator
Biomarkers of Thrombosis as Predictors of Venous Thromboembolism Risk in Cancer Patients
Role: collaborator
Adherence and Coagulation Assays in Dabigatran-treated Patients With Atrial Fibrillation
Role: collaborator
Apixaban Validation Study - Additional Study on Fresh Samples
Role: lead
Validation of Rivaroxaban Assay for US Registration
Role: lead
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
Role: lead
Characterization of Hemostatic Disordres in Septic Shock: Searching for Biological Markers
Role: collaborator
Measurement of D-Dimer Levels in Patients With Confirmed Deep Vein Thrombosis
Role: lead
Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy
Role: collaborator
All 13 trials loaded